CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

berubicin (RTA 744) - CNS Pharma, WPD Pharma

Jan 17, 2024